基于功能状态的肥胖分型与乳腺癌风险的前瞻性队列研究
基于中国开滦前瞻性队列19 921名女性职工,按《柳叶刀》临床肥胖委员会功能状态肥胖标准分为非肥胖、临床前肥胖和临床肥胖组,中位随访16.95年确诊379例乳腺癌。临床前肥胖和临床肥胖均增加乳腺癌风险,该关联在≤50岁人群中更明显。
要点
- 临床前肥胖和临床肥胖均增加女性乳腺癌发病风险
- 肥胖与年龄存在交互作用,≤50岁女性风险升高更明显
- 临床前肥胖的识别与干预可为乳腺癌一级预防提供新窗口
核心结论
- 临床前肥胖与临床肥胖均增加女性乳腺癌发病风险,肥胖对乳腺癌的致癌作用可能具有功能状态依赖性。
- 该关联在≤50岁人群中更为明显,临床前肥胖的识别与干预可为乳腺癌一级预防提供新的窗口期。
研究设计与样本
- 基于中国开滦前瞻性队列,纳入2006年首次参加开滦健康体检的19 921名女性职工。
- 根据《柳叶刀》临床肥胖委员会提出的功能状态肥胖分型标准分为非肥胖组(n=9 366)、临床前肥胖组(n=5 061)、临床肥胖组(n=5 494)。
- 采用Kaplan-Meier法和Log-rank检验比较乳腺癌累积发病率,采用Cox回归模型评估关联,并按年龄、绝经状态分层分析。
主要发现
- 随访截至2023年12月31日,共确诊乳腺癌379例,中位随访时间16.95年。
- 非肥胖组、临床前肥胖组和临床肥胖组乳腺癌新发病例数分别为144、105和130例,累积发病率依次为0.93%、1.26%和1.49%(χ²=15.73,P<0.001)。
- 多因素Cox回归校正年龄、生活方式、家族史、服药情况后,以非肥胖组为参照,临床前肥胖组HR=1.32(95% CI:1.02~1.71),临床肥胖组HR=1.60(95% CI:1.22~2.09)。
- 肥胖状态与年龄间存在交互作用(χ²=7.22,P=0.027);≤50岁女性临床前肥胖组和临床肥胖组HR分别为1.52和2.06(均P<0.05),>50岁人群中未见明显关联。
- 肥胖与绝经状态交互作用不显著(χ²=5.38,P=0.068),但绝经前女性中临床肥胖组HR=1.67(95% CI:1.11~2.52)。
关键数值与推荐
- 功能状态肥胖分型依据《柳叶刀》临床肥胖委员会标准,分为非肥胖、临床前肥胖和临床肥胖。
- 累积发病率组间比较:χ²=15.73,P<0.001。
- 多因素Cox回归:临床前肥胖组HR=1.32(95% CI:1.02~1.71),临床肥胖组HR=1.60(95% CI:1.22~2.09)。
- 年龄交互作用:χ²=7.22,P=0.027;≤50岁临床前肥胖组HR=1.52、临床肥胖组HR=2.06(均P<0.05)。
- 敏感性分析剔除随访2年内新发病例(n=78)后,临床肥胖组HR=1.59(95% CI:1.20~2.10),临床前肥胖组HR=1.23(95% CI:0.94~1.61)。
临床怎么用
- 在乳腺癌风险评估中可结合功能状态肥胖分型识别高危女性。
- 对≤50岁女性,尤其应关注临床前肥胖和临床肥胖状态。
- 临床前肥胖可作为乳腺癌一级预防的潜在干预窗口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the association between different functional status-based obesity classifications and the risk of breast cancer in women. Methods: Based on the prospective Kailuan cohort in China, this study included 19 921 female employees who first participated in the Kailuan health examination in 2006. According to the functional status-based obesity criteria proposed by the Lancet Commission on Clinical Obesity, participants were divided into the non-obesity group (n=9 366), preclinical obesity group (n=5 061), and clinical obesity group (n=5 494). The Kaplan-Meier analysis and the Log-rank test were used to compare the cumulative incidence of breast cancer among the groups. Cox regression models were employed to evaluate the associations between different functional status-based obesity classifications and breast cancer risk, with stratified analyses by age and menopausal status. Results: By the end of follow-up on December 31, 2023, a total of 379 incident breast cancer cases were confirmed, with a median follow-up of 16.95 years. The numbers of new breast cancer cases in the non-obesity, preclinical obesity, and clinical obesity groups were 144, 105 and 130, respectively, with cumulative incidence rates of 0.93%, 1.26%, and 1.49%, respectively (χ²=15.73, P<0.001). In the multivariable Cox regression model adjusted for age, lifestyle factors, family history, and medication use, using the non-obesity group as the reference, the risks of breast cancer were progressively higher in the preclinical obesity group (HR=1.32, 95% CI: 1.02-1.71) and the clinical obesity group (HR=1.60, 95% CI: 1.22-2.09). After adding a multiplicative interaction term between obesity classification and age to the multivariable Cox regression model, a significant interaction was observed between obesity status and age (χ²=7.22, P=0.027). In age-stratified analyses, among women aged ≤50 years, both the preclinical obesity group and the clinical obesity group showed increased risk of breast cancer (HR=1.52 and 2.06, respectively; both P<0.05), whereas no significant associations were observed in women aged >50 years. The interaction between obesity phenotype and menopausal status was not statistically significant (χ²=5.38, P=0.068); however, among premenopausal women, the clinical obesity group had an increased risk of breast cancer (HR=1.67, 95% CI: 1.11-2.52). In a sensitivity analysis excluding cases diagnosed within 2 years of follow-up (n=78), the clinical obesity group remained an increased risk of breast cancer (HR=1.59, 95% CI: 1.20-2.10), while the association for the preclinical obesity group was no longer statistically significant (HR=1.23, 95% CI: 0.94-1.61). Conclusions: Both preclinical obesity and clinical obesity increase the risk of breast cancer in women, suggesting that the carcinogenic effect of obesity on breast cancer may be dependent on functional status. The association is more pronounced in women aged ≤50 years. The identification and intervention of preclinical obesity may provide a novel window of opportunity for primary prevention of breast cancer. 目的: 探讨不同功能状态肥胖分型与女性乳腺癌发病风险的关联。 方法: 基于中国开滦前瞻性队列,纳入2006年首次参加开滦健康体检的19 921名女性职工,根据《柳叶刀》临床肥胖委员会提出的功能状态肥胖分型标准将研究对象分为非肥胖组(n=9 366)、临床前肥胖组(n=5 061)、临床肥胖组(n=5 494)。采用Kaplan-Meier法和Log-rank检验比较乳腺癌累积发病率的组间差异。采用Cox回归模型评估不同功能状态肥胖分型与乳腺癌发病风险的关联,并按照年龄、绝经状态进行分层分析。 结果: 随访截至2023年12月31日,共确诊乳腺癌379例,中位随访时间16.95年。非肥胖组、临床前肥胖组和临床肥胖组乳腺癌新发病例数分别为144、105和130例,累积发病率依次为0.93%、1.26%和1.49%(χ²=15.73,P<0.001)。多因素Cox回归模型校正年龄、生活方式、家族史、服药情况后,以非肥胖组为参照,临床前肥胖组与临床肥胖组的乳腺癌发病风险依次升高(HR=1.32,95% CI:1.02~1.71;HR=1.60,95% CI:1.22~2.09)。在多因素Cox回归模型基础上加入肥胖分型与年龄的相乘交互项,结果显示,肥胖状态与年龄间存在交互作用(χ2=7.22,P=0.027),按年龄分层后,≤50岁女性临床前肥胖组和临床肥胖组乳腺癌风险升高(HR分别为1.52和2.06;均P<0.05),>50岁人群中未见明显关联。肥胖与绝经状态交互作用不显著(χ2=5.38,P=0.068),但在绝经前女性中,临床肥胖组乳腺癌风险升高(HR=1.67,95% CI:1.11~2.52)。剔除随访2年内新发病例(n=78)进行敏感性分析,结果显示,临床肥胖组乳腺癌发病风险仍升高(HR=1.59,95% CI:1.20~2.10),临床前肥胖组无统计学意义(HR=1.23,95% CI:0.94~1.61)。 结论: 临床前肥胖与临床肥胖均增加女性乳腺癌发病风险,肥胖对乳腺癌的致癌作用可能具有功能状态依赖性,该关联在≤50岁人群中更为明显,临床前肥胖的识别与干预可为乳腺癌一级预防提供新的窗口期。.
引用
- Ding S, Hao JY, Wang MJ, et al. [Association between functional status-based obesity classification and breast cancer risk: a prospective cohort study]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42927949. doi:10.3760/cma.j.cn112152-20250919-00470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。